5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.46▼ | 1.45▼ | 1.44▼ | 1.47▲ | 1.46▲ |
MA10 | 1.45▼ | 1.44▼ | 1.44▼ | 1.47▲ | 1.52▼ |
MA20 | 1.44▼ | 1.44▼ | 1.44▼ | 1.44▲ | 1.79▼ |
MA50 | 1.44▼ | 1.49▼ | 1.54▼ | 1.56▼ | 4.07▼ |
MA100 | 1.48▼ | 1.74▼ | 1.83▼ | 1.82▼ | 13.75▼ |
MA200 | 1.78▼ | 2.00▼ | 1.95▼ | 3.69▼ | 33.08▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.008▲ | 0.010▲ | 0.017▲ | 0.190▲ |
RSI | 45.598▼ | 45.210▼ | 44.918▼ | 50.671▲ | 36.555▼ |
STOCH | 34.616 | 37.068 | 35.769 | 52.419 | 15.559▼ |
WILL %R | -92.308▼ | -70.796 | -78.422▼ | -39.976 | -90.338▼ |
CCI | -94.677 | 22.260 | -3.507 | 115.915▲ | -54.771 |
RSI | $NLSP RSI(14) Crossed Above 50 | Set Alert |
Monday, April 28, 2025 05:29 AM
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Technology, Consumer Services and Industrials ...
|
Thursday, April 24, 2025 05:00 PM
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous ...
|
Thursday, April 24, 2025 05:00 PM
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 1.47 | 1.56 | 1.47 | 1.50 | 13,477 |
30/04/25 | 1.52 | 1.52 | 1.46 | 1.472 | 5,447 |
29/04/25 | 1.50 | 1.50 | 1.42 | 1.42 | 28,802 |
28/04/25 | 1.51 | 1.51 | 1.47 | 1.47 | 5,475 |
25/04/25 | 1.4601 | 1.53 | 1.46 | 1.50 | 11,522 |
24/04/25 | 1.46 | 1.50 | 1.4305 | 1.50 | 24,874 |
23/04/25 | 1.44 | 1.525 | 1.44 | 1.47 | 47,425 |
22/04/25 | 1.44 | 1.47 | 1.38 | 1.43 | 14,747 |
21/04/25 | 1.46 | 1.4612 | 1.429 | 1.45 | 19,263 |
17/04/25 | 1.45 | 1.46 | 1.3927 | 1.46 | 17,315 |
|
|
||||
|
|
||||
|
|